

Title (en)

Human antithrombin III, DNA sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin III, and pharmaceutical compositions comprising it.

Title (de)

Menschliches Antithrombin III, DNS Sequenzen dafür, Expressions- und Klonierungsvektoren die solche Sequenzen enthalten und damit transformierte Zellkulturen, Verfahren zur Expression von Menschlichem Antithrombin III und diese enthaltende pharmazeutische Zusammensetzungen.

Title (fr)

Antithrombine III humaine, séquences d'ADN pour celli-ci, vecteurs de clonage et d'expression contenant ces sequences et cultures de cellules transformées par ceux-ci, procédé pour exprimer l'antithrombine III humaine et compositions pharmaceutiques la contenant.

Publication

EP 0090505 A2 19831005 (EN)

Application

EP 83301108 A 19830302

Priority

- GB 8206262 A 19820303
- US 40360082 A 19820730

Abstract (en)

Human antithrombin III, and aspects concerning its preparation via recombinant DNA technology, form the basis of this disclosure. The disclosed methodology makes possible the preparation of useful quantities of the compound for applications in maintaining the fluidity of blood.

IPC 1-7

C12N 15/00; **C12P 21/02**; **C07C 103/52**; **C12N 5/00**; **A61K 37/64**

IPC 8 full level

A61K 35/74 (2006.01); **A61K 38/16** (2006.01); **A61K 38/55** (2006.01); **A61P 7/02** (2006.01); **C07H 21/00** (2006.01); **C07H 21/02** (2006.01); **C07K 14/00** (2006.01); **C07K 14/47** (2006.01); **C07K 14/81** (2006.01); **C12N 1/21** (2006.01); **C12N 15/00** (2006.01); **C12N 15/09** (2006.01); **C12P 21/02** (2006.01); **A61K 38/00** (2006.01); **C12R 1/19** (2006.01)

CPC (source: EP)

A61P 7/02 (2017.12); **C07K 14/8128** (2013.01); **A61K 38/00** (2013.01)

Cited by

US5700663A; EP0248359A1; US4663285A; US2011082083A1; EP0256302A3; US6066781A; EP0190652A1; US4849349A; EP0257630A1; AU2019278998B2; US11517623B2; WO2016014565A2; WO2018073753A1; WO2018201056A1; WO2020047452A2; WO2020132649A1; WO2021026098A1; WO2021108661A2; WO2023154905A1; WO2016014553A1; WO2017149515A1; WO2020051333A1; WO2020050890A2; WO2020106640A1; WO2021026100A1; US11053226B2; US11285156B2; EP4036109A2; WO2017112741A1; WO2018060926A1; WO2020102730A1; EP3698796A1; US11299491B2; EP4234546A2; WO2015142675A2; WO2016044605A1; WO2016126608A1; WO2017040930A2; WO2018187227A1; EP3967709A1; US7510828B2; US11571459B2; WO2016040880A1; WO2017015427A1; WO2019006427A1; WO2019118937A1; WO2020132648A1; WO2021026101A1; US11236069B2; EP4268898A2; WO2015107495A1; WO2017117112A1; WO2019129137A1; WO2019227003A1; WO2020065453A1; WO2020102770A1; US11667613B2; EP4282416A2; WO2024031091A2; WO2016014530A1; WO2017216685A1; WO2017223422A1; WO2018057585A1; WO2020053654A1; WO2020160050A1; US11072610B2; US11236091B2; US11827635B2; WO2016025880A1; WO2016090034A2; WO2017079115A1; WO2017079116A2; WO2017079112A1; WO2017216686A1; WO2018128939A1; WO2019089969A2; WO2019166951A1; US10537637B2; WO2020219742A1; WO2021108683A1; WO2021108613A1; EP4046655A1; WO2017140821A1; WO2018226336A1; WO2019089858A2; US10597453B2; WO2020092848A2; WO2020092854A2; US10647773B2; US11001635B2; WO2021173995A2; WO2022125497A1; US11518813B2; US11667716B2; US11945873B2; US8563693B2; WO2018217651A1; WO2019241426A1; US10519146B2; EP3974429A1; US11905281B2; WO2015073644A1; WO2015148379A1; WO2016164580A1; WO2016172583A1; WO2019051291A1; EP3511328A1; WO2020069409A1; US10640504B2; WO2020132651A1; EP3722316A1; US11306087B2; WO2022254337A1; EP4141005A1; US11993597B2; WO2014153270A1; WO2017216705A1; WO2018067992A1; US10071973B2; WO2018201051A1; EP3514179A1; EP3539986A1; WO2020210678A1; US10851157B2; WO2020263312A1; WO2021163618A1; US11365252B2; EP4067382A1; US12018073B2; WO2015090230A1; WO2016100882A1; WO2016168595A1; WO2018119183A2; WO2018198079A1; WO2019084288A1; US10301312B2; WO2019109053A1; WO2019213282A1; WO2019217691A1; US10532042B2; WO2020047449A2; WO2020069405A1; US10975078B2; US10988485B2; WO2021207689A2; US11285135B2; EP3998269A1; EP4001269A1; EP4026909A1; EP4234685A2; WO2023250400A1; WO2016097995A1; WO2018047109A1; WO2018102787A1; WO2018203302A1; WO2019213526A1; WO2019232419A1; EP3660042A1; WO2020132653A1; WO2021097207A1; US11045484B2; US11096939B2; WO2023039089A1; EP4205749A1; EP4279136A2; WO2015066413A1; WO2017163186A1; US10034921B2; WO2019213516A1; WO2020106647A2; US10894823B2; WO2021081212A1; WO2021097212A1; US11090304B2; US7494782B2; US11426404B2; US11439645B2; US11766436B2; EP4292658A2; US11918584B2; WO2024129778A2; WO2015138920A1; WO2016057705A1; WO2016061142A1; WO2016164731A2; WO2019123285A1; WO2019210153A1; EP3660050A1; EP3712171A1; WO2021026099A1; US11234977B2; EP4056588A1; WO2022261018A1; EP4245376A2; EP4324518A2; WO2015157252A1; WO2016020836A1; WO2017103895A1; WO2018223101A1; WO2019090003A1; WO2019097479A1; WO2020113194A2; EP3888674A1; WO2022104061A1; US11413310B2; WO2022235866A1; US11944647B2; WO2024081916A1

Designated contracting state (EPC)

AT BE CH DE FR GB IT LI LU NL SE

DOCDB simple family (publication)

EP 0090505 A2 19831005; **EP 0090505 A3 19840222**; **EP 0090505 B1 19900808**; DE 3381783 D1 19900913; GB 2116183 A 19830921; GB 2116183 B 19850605; GB 8305786 D0 19830407; JP 2515468 B2 19960710; JP H05279398 A 19931026; JP H0687778 B2 19941109; JP S58162529 A 19830927

DOCDB simple family (application)

EP 83301108 A 19830302; DE 3381783 T 19830302; GB 8305786 A 19830302; JP 20108392 A 19920728; JP 3390083 A 19830303